

|   |                        |                     |
|---|------------------------|---------------------|
| <b>Examiner-Initiated Interview Summary</b> | <b>Application No.</b> | <b>Applicant(s)</b> |
|   | 08/484,786             | MACH ET AL.         |
| <b>Examiner</b>                             | <b>Art Unit</b>        |                     |
| Jehanne Souaya Sitton                       | 1634                   |                     |

**All Participants:**

(1) Jehanne Souaya Sitton.

(3) \_\_\_\_\_.

(2) Shawn-Marie Mayrand.

(4) \_\_\_\_\_.

**Date of Interview:** 19 April 2004

**Time:** \_\_\_\_\_

**Type of Interview:**

- Telephonic
- Video Conference
- Personal (Copy given to:  Applicant     Applicant's representative)

Exhibit Shown or Demonstrated:  Yes     No

If Yes, provide a brief description: .

**Part I.**

Rejection(s) discussed:

*112/first paragraph, Written Description*

Claims discussed:

*103, 105*

Prior art documents discussed:

*NA*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner indicated that upon further review, the claims should be amended to recite nucleic acid sequences from the regions encoding each peptide so as to distinguish a nucleic acid sequence which encoded a region I peptide from a nucleic acid sequence which encoded a region II peptide or a region III peptide, for example. The examiner indicated that the specific regions I, II, and III are set forth in figure 9 as well as pages 7 and 32 of the specification. Applicants representative authorized the changes set forth in the attached examiner's amendment. .